-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Graphite Bio PT From RBC Cut to $4 From $11 as Sickle Cell Disease Trial Pauses Amid Serious Adverse Event; Sector Perform, Speculative Risk Kept

Graphite Bio PT From RBC Cut to $4 From $11 as Sickle Cell Disease Trial Pauses Amid Serious Adverse Event; Sector Perform, Speculative Risk Kept

MT Newswires · 01/06/2023 03:40